Zafgen (ZFGN) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Zafgen Reports Second Quarter 2017 Financial Results
August 8, 2017 4:06 PM EDT-ZGN-1061 Phase 1 Data Support Continued Development for Obese Patients with Type 2 Diabetes-
-Company to Initiate Phase 2 Clinical Trial in Third Quarter of This Year-
-Ends Quarter with Cash, Cash Equivalents and Marketable Securities of $106 Million; Increases Year-End Cash Guidance to Greater than $70 Million-
BOSTON, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq: ZFGN), today announced its second quarter 2017 financial results.
In the second quarter, we reached a critical milestone in the development program for ZGN-1061,... More
